High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.

IF 5.6 1区医学 Q1 Medicine

Breast Cancer Research Pub Date : 2025-08-11 DOI:10.1186/s13058-025-02092-9

Amadeo M Parissenti, Laura B Pritzker, Maria Aanesland Dahle, Hedda von der Lippe Gythfeldt, Twinkle Masilamani, Gabriel Theriault, Renée St-Onge, Lavina D'costa, Ole Christian Lingjaerde, Mads Haugland Haugen, Olav Engebraaten

引用次数: 0

查看原文本刊更多论文

her2阴性乳腺癌患者治疗中期肿瘤RNA破坏与新辅助化疗后无病生存率的提高相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Research ONCOLOGY-

CiteScore

12.00

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： Breast Cancer Research, an international, peer-reviewed online journal, publishes original research, reviews, editorials, and reports. It features open-access research articles of exceptional interest across all areas of biology and medicine relevant to breast cancer. This includes normal mammary gland biology, with a special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal covers preclinical, translational, and clinical studies with a biological basis, including Phase I and Phase II trials.